Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Last trade$4.82
Day change-$0.325 (-6.32%)
Day range$4.79 – $5.13
Volume950,311
Market cap$667M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$667.28M
Price / earnings
—
Price / book
1.76×
Price / sales
92.18×
EV / sales
84.21×
EV / EBITDA
-1.53×
Profitability
Earnings per share
-$3.26
Return on assets
-86.61%
Return on equity
-111.85%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.57×
Quick ratio
5.57×
Cash ratio
0.73×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$320.93M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALMS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.91M
$1.66M
$1.74M
$1.93M
$2.07M
$2.67M
$17.39M
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.91M
$1.66M
$1.74M
$1.93M
$2.07M
$2.67M
$17.39M
$0
Selling, general and administrative
$20.19M
$23.36M
$18.61M
$15.59M
$19.52M
$34.45M
$22.3M
$11.42M
Research and development
$80.79M
$85.34M
$81.54M
$82.79M
$97.84M
$108.76M
$96.62M
$87.2M
Total operating expenses
$100.98M
$150.52M
$100.15M
$98.37M
$117.36M
$143.21M
$118.92M
$98.62M
Operating income
-$99.08M
-$148.86M
-$98.41M
-$96.45M
-$115.29M
-$140.54M
-$101.53M
-$98.62M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$94.88M
-$143.98M
-$93.05M
-$92.93M
-$110.75M
$50.76M
-$98.96M
-$94.76M
Income taxes
$0
-$1.76M
$0
$0
$0
-$8.56M
$0
$0
Net income
-$94.88M
-$142.22M
-$93.05M
-$92.93M
-$110.75M
$59.32M
-$98.96M
-$94.76M
Net income attributable to common shareholders
-$94.88M
-$142.22M
-$93.05M
-$93.13M
-$110.75M
$59.32M
-$98.96M
-$94.9M
EBITDA
-$98.19M
-$106.16M
-$97.54M
-$95.58M
-$114.38M
-$139.67M
-$100.69M
-$97.8M
Basic earnings per share
-$0.73
-$1.11
-$0.74
-$0.88
-$1.06
$0.78
-$1.82
-$1.73
Diluted earnings per share
-$0.73
-$1.11
-$0.74
-$0.89
-$1.06
$0.77
-$1.82
-$1.73
Recent news
Company coverage with links to the original publishers.
Cormorant Asset Management increased its stake in Alumis by 313,645 shares ($7.84 million) in Q1 2026, bringing its position to 4.37% of assets. Alumis shares have surged 400% over the past year, driven by strong Phase 3 psoriasis trial data for its lead drug envudeucitinib. The company has $569.5 million in cash and plans to submit an NDA in Q4 2026, with pivotal lupus data expected in Q3.
Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.
Alumis announced positive Phase 3 results for envudeucitinib, a TYK2 inhibitor for moderate-to-severe plaque psoriasis. The drug achieved PASI 90 responses in 68.0% and 62.1% of patients by Week 24, with PASI 100 complete clearance in 41.0% and 39.5%. Quality-of-life improvements and itch relief emerged early, with a favorable safety profile. The company plans to submit an NDA to the FDA in the second half of 2026.
Alumis Inc., a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 17.65 million shares at $17.00 per share, generating approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, with underwriters granted a 30-day option to purchase an additional 2.65 million shares. Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are serving as joint book-running managers.
Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0.62% and Nasdaq up 0.65%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.